[Substitution of antithrombin III by synthetic thrombin inhibitors].
Synthetic, low-molecular weight thrombin inhibitors may substitute for antithrombin III in inactivating thrombin in vitro and in vivo. They are superior to heparin as antithrombotic agents in antithrombin deficiency or consumption. Studies in experimental animals show the effectiveness of synthetic thrombin inhibitors in immunologic antithrombin depletion, thrombin-induced consumption and CCl4-induced liver failure.
D000818:Animals; D000990:Antithrombin III / Q000627:therapeutic use*; D020152:Antithrombin III Deficiency; D001120:Arginine / Q000031:analogs & derivatives; D002252:Carbon Tetrachloride Poisoning / Q000097:blood; D005340:Fibrinogen / Q000378:metabolism; D006493:Heparin / Q000627:therapeutic use; D010667:Phenylpyruvic Acids / Q000627:therapeutic use; D010875:Pipecolic Acids / Q000627:therapeutic use; D010976:Platelet Count; D051381:Rats; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*
D010667:Phenylpyruvic Acids; D010875:Pipecolic Acids; D013449:Sulfonamides; C006492:amidinophenylpyruvic acid; C028615:ethyl 4-amidinophenylpyruvate; D000990:Antithrombin III; D005340:Fibrinogen; D006493:Heparin; D001120:Arginine; D013917:Thrombin; C031942:argatroban
Substitution von Antithrombin III durch synthetische Thrombininhibitoren.